(6S,11R)-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol

ID: ALA3085528

Chembl Id: CHEMBL3085528

PubChem CID: 10016044

Max Phase: Preclinical

Molecular Formula: C18H25NO

Molecular Weight: 271.40

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC1CC1

Standard InChI:  InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3/t12-,17+,18-/m0/s1

Standard InChI Key:  YQYVFVRQLZMJKJ-RZAIGCCYSA-N

Associated Targets(Human)

OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Mu opioid receptor (3620 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Kappa opioid receptor (4577 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 G_PROTEIN_RECEP_F1_2 domain-containing protein (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 271.40Molecular Weight (Monoisotopic): 271.1936AlogP: 3.33#Rotatable Bonds: 2
Polar Surface Area: 23.47Molecular Species: BASEHBA: 2HBD: 1
#RO5 Violations: HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 9.94CX Basic pKa: 10.78CX LogP: 2.92CX LogD: 0.81
Aromatic Rings: 1Heavy Atoms: 20QED Weighted: 0.89Np Likeness Score: 1.43

References

1. Wentland MP, Xu G, Cioffi CL, Ye Y, Duan W, Cohen DJ, Colasurdo AM, Bidlack JM..  (2000)  8-Aminocyclazocine analogues: synthesis and structure-activity relationships.,  10  (2): [PMID:10673107] [10.1016/s0960-894x(99)00670-8]
2. Crivori P, Cruciani G, Carrupt PA, Testa B..  (2000)  Predicting blood-brain barrier permeation from three-dimensional molecular structure.,  43  (11): [PMID:10841799] [10.1021/jm990968+]
3. Wentland MP, Lou R, Ye Y, Cohen DJ, Richardson GP, Bidlack JM..  (2001)  8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.,  11  (5): [PMID:11266156] [10.1016/s0960-894x(01)00014-2]
4. VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM..  (2007)  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.,  17  (23): [PMID:17935988] [10.1016/j.bmcl.2007.09.082]
5. Katz R, Osborne SF, Ionescu F..  (1977)  Application of the Free-Wilson technique to structurally related series of homologues. Quantitative structure-activity relationship studies of narcotic analgetics.,  20  (11): [PMID:21292] [10.1021/jm00221a012]
6. Turnaturi R, Marrazzo A, Parenti C, Pasquinucci L..  (2018)  Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review.,  148  [PMID:29477074] [10.1016/j.ejmech.2018.02.046]

Source